Today NVAX is selling for a tiny fraction of its all-time high as shown in a previous idea. Earnings is coming this upcoming week. This week NVAX news release showed it had settled a years long litigation over a failed COVID. In the face of earnings around the corner, was this news release a coincidence or instead a case of excellent executive and legal...
After the very good results of the first quarter,the stock reacted well. The hepatitis cases remain under control. The company's balance sheet is clean and this gives hope for the future...
There is something that market is wrong about. The VIR and its blockbuster drug. This drug earns $1-1.5B per Q. + they are clinical stage company with Huuge innovative pipeline in HBV and HIV - treatments and VACCINES! And market prices them like @#$! while they will earn around their own 1x market cap in 2022 and will sit with so much cash, that the current...
Analysis for VIR Two falling wedges can be seen to have formed in this current down move As in the previous down move, price temporarily moves out of the channel before moving back up This is what's occurring now with this second falling wedge I do expect a big break out at this huge support area
VIR has a couple of interesting products testing in the pipeline. The one that caused the spike in Jan is for hepatitis B treatment. And the selloff today is caused by the pause in the enrollment of late-stage trial testing of their Covid19 antibody. So it seems it is safe to assume that it will return above previous resistance of 53. With 80's as a first target,...
SPCE VIR AND XPEL I TALK ABOUT HOW TO TRADE THEM
My watch list for the week SPCE and two pharmaceutical companies VIR DNLI because of the Corona virus